Navigation Links
Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
Date:4/26/2011

tment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").  The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy.
  • Met with officials of the FDA's OND and presented arguments supporting CTI's belief that the data contained in its NDA 22-481 supports the conclusion that pixantrone is effective for its planned use. CTI expects a decision on its appeal during the second quarter of 2011.
  • Received the day 120 list of questions from the EMA relating to our MAA for pixantrone in Europe.

  • For the quarter ended March 31, 2011, total operating expenses decreased to $20.1 million compared to $25.8 million for the same period in 2010.  Research and development expenses increased to $11.5 million in the quarter ended March 31, 2011 compared to $7.4 million for the same period in 2010 due to a one-time upfront payment of $5.0 million related to the licensing of tosedostat from Chroma in 2011. Selling, general and administrative expenses decreased to $8.6 million in the quarter ended March 31, 2011 compared to $18.4 million for the same period in 2010 primarily related to a decrease in non-cash equity based compensation. Net loss attributable to common shareholders was $51.0 million ($0.06 per share) for the quarter ended March 31, 2011 compared to a net loss attributable to common shareholders of $44.2 million ($0.07 per share) for the same period in 2010. The increase in net loss attributable to common shareholders is mainly due to an increase in non-cash deemed dividends on preferred stock related to financing activities.

    CTI had approximately $43.8 million in cash and cash equivalents as of March 31, 2011.Conference Call InformationOn Wednesday, April 27, 2011, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
    2. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
    3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
    4. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
    5. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
    6. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
    7. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
    8. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
    9. BioMarin Acquires ZyStor Therapeutics, Inc.
    10. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
    11. Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
    (Date:11/24/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), a ... and vascular surgery, announced today that it will participate in ... on Wednesday, December 3, 2014 at The New York Palace ... A live webcast of the Company,s presentation is scheduled ... overview of the company by Pat Mackin , President ...
    (Date:11/24/2014)... MONTREAL , Nov. 24, 2014 /PRNewswire/ - Milestone ... clinical trial conducted in Melbourne, Australia ... antagonist for the potential treatment of paroxysmal supraventricular ... formulation of MSP-2017 was well tolerated at single ... an excellent safety profile, desirable PK properties including ...
    Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
    ... , , ... (Nasdaq: IPCM ), a leading national hospitalist physician group practice ... was named by ACP Hospitalist as one of the ... the November 2009 issue of the magazine. , Dr. Vaidyan has ...
    ... VIEW, Calif., Nov. 24 Satellite Healthcare, one of the ... a major sponsor of nephrology research, today announced its full ... his effort to support the San Jose homeless this Thanksgiving ... chef for the past 20 years. But Nasrallah,s life was ...
    Cached Medicine Technology:IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 3Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2
    (Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
    (Date:11/26/2014)... Vultures have developed highly specialized ways of dealing with ... researchers report. The new research investigated the different ... the guts of 50 turkey vultures and black vultures ... the vultures had more than 500 different types of ... found. The findings suggest that a vulture,s digestive ...
    (Date:11/26/2014)... to peanut protein in household dust may increase the ... condition eczema, a new study reveals. About 2 ... allergic to peanuts. And severe eczema in infants has ... researchers noted. The new study included 359 infants ... the amount of peanut protein the children were exposed ...
    (Date:11/26/2014)... News) -- Parents need to take an active role ... warns. Parents must make sure sports-playing teens have ... Dodick, chair of the American Migraine Foundation and a ... Medicine in Scottsdale, Ariz. in an American Migraine Foundation, ... coach involved with teens sports needs to have appropriate ...
    (Date:11/24/2014)... 24, 2014 The Healthy Skin Care ... of affordable skin care products, recently announced its launch. ... readers a wide variety of articles, tips, and evaluations ... organic skincare alternatives. , According to Emily Lataille, the ... content includes thoroughly researched reviews, tips for the skin, ...
    Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2
    ... , BETHESDA, Md., Nov. 16 GetWellNetwork, Inc. ... chief operating officer. Ms. Perry, an experienced high-tech leader and ... level of growth and deliver on the promise of improving ... Among her priorities, Ms. Perry will focus on GetWellNetwork,s leadership ...
    ... extended-release niacin, or Niaspan , SUNDAY, Nov. 15 (HealthDay ... ezetimibe (Zetia), a drug used by millions of Americans ... cholesterol. , The trial, known as ARBITER-6 HALTS, was ... LDL-cholesterol-lowering Zetia was less effective than extended-release niacin (Niaspan), ...
    ... 16 Blue Water Spa, a Raleigh NC Day Spa and ... party and Raleigh food drive. Guests who donate frozen turkeys or ... receive a $10,000 spa gift certificate for luxury spa services. , ... on hand Wed. November 18 and Saturday December 12 to accept ...
    ... YORK, Nov. 16 Nearly every household has some sort of ... like. But how many people plan ahead for dental emergencies? ... leading provider of oral care products, although one in six Americans ... not prepared to deal with the problem. , "You keep ...
    ... ... researchers with online cognitive rehab tools for cognitive impairments caused by Alzheimer,s disease, Traumatic ... ... HAPPYneuron PRO, a suite of online cognitive rehab tools for a variety ...
    ... ... Socks for Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive ... marketplace debut and the launch of “Cool Clothes for Toes,” the first creatively styled sock ...
    Cached Medicine News:Health News:GetWellNetwork Taps High-Tech Veteran Michele Perry as Chief Operating Officer 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Raleigh Day Spa, Blue Water Spa, Raffles Off $10,000 in Day Spa Packages for Contributing to Raleigh Food Drive 2Health News:Be Prepared for a Dental Emergency During the Holidays 2Health News:HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco 2Health News:HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco 3Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3
    The PowerLab/4ST is a high-performance recording unit with built-in amplifiers and is suitable for physiology teaching. It has been designed to cover the broad experimental requirements in life scien...
    ... The PowerLab/4SP is a high-performance data acquisition ... research applications including human and animal physiology, ... engineering. The unit is capable of recording ... (up to 200 000 samples per second ...
    Worth 4-Dot Flashlight/Plastic for testing and training of visual functions and testing for fusion, suppression and/or diplopia. Red/green goggle included. Requires 2 C batteries (not included)....
    They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
    Medicine Products: